1
项与 CLL1 and CD38 dual-target CAR-T(Gracell Biotechnology Shanghai) 相关的临床试验Clinical Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T Injection in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
This study is a single-center clinical study. The main purpose is an IIT clinical trial to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual CAR-T injection in r/r AML subjects . The included population were patients with relapsed and refractory acute myeloid leukemia (r/r AML) .
100 项与 CLL1 and CD38 dual-target CAR-T(Gracell Biotechnology Shanghai) 相关的临床结果
100 项与 CLL1 and CD38 dual-target CAR-T(Gracell Biotechnology Shanghai) 相关的转化医学
100 项与 CLL1 and CD38 dual-target CAR-T(Gracell Biotechnology Shanghai) 相关的专利(医药)
100 项与 CLL1 and CD38 dual-target CAR-T(Gracell Biotechnology Shanghai) 相关的药物交易